State Street Corp Cti Biopharma Corp Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.2 - $6.01 $15 Million - $21.4 Million	-3,565,711 Reduced 22.28%	12,437,278 $52.2 Million
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $10.1 Million - $13.9 Million	2,260,435 Added 16.45%	16,002,989 $96.2 Million
Q3 2022 Nov 15, 2022	BUY	$5.36 - $7.43 $20.9 Million - $28.9 Million	3,893,026 Added 39.53%	13,742,554 $80 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $34 Million - $60.1 Million	9,578,193 Added 3530.02%	9,849,528 $58.8 Million
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $110,239 - $303,449	58,021 Added 27.2%	271,335 $1.27 Million
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.18 $107,775 - $152,322	47,900 Added 28.96%	213,314 $629,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $2.62 $311,605 - $377,966	144,262 Added 682.03%	165,414 $414,000
Q1 2021 May 17, 2021	BUY	$2.68 - $3.8 $8,308 - $11,780	3,100 Added 17.17%	21,152 $62,000
Q1 2020 May 11, 2020	BUY	$0.69 - $1.54 $12,455 - $27,800	18,052 New	18,052 $17,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.